Analysis of “Calcium butyrate efficacy in pediatric irritable bowel syndrome”

We read with interest the article by Cristofori et al., demonstrating the potential benefit of butyrate in pediatric irritable bowel syndrome (IBS).1 The reported treatment success rate (73%) exceeds those typically observed in randomized controlled trials of dietary or pharmacologic interventions in pediatric IBS, whereas the placebo response (3.8%; Faces Pain Scale [FPS]-guided ΔVisual Analogue Scale (VAS) = −0.28) is considerably lower than meta-analytic estimates (41% improvement, 17% complete relief, pooled FPS change −0.73; 95% confidence interval [CI], −1.04 to −0.42).2-5 Several methodological aspects may help explain this. The exclusion criteria did not specifically exclude concurrent interventions (e.g., psychosocial therapies), potentially confounding outcomes.6 The sample size calculation lacked detailed assumptions, contributing to a small sample size more susceptible to baseline imbalance (such as the significantly lower pain severity scores in the placebo group) and random variation. Reporting of details on randomization procedures was limited, specifically on allocation concealment, which differs from blinding and is often lacking in blinded studies. Further uncertainties include the content of placebo capsules, compliance with medication and pain diaries—often noteworthy low in pediatric studies—and handling of missing data.7 The timing of measuring treatment success was also unclear, particularly whether values reflected single-day scores, extreme values, or the recommended 7-day averages.8 Finally, although not industry-sponsored, active and placebo treatment were provided by the butyrate manufacturer, and the extent of involvement in study conduct was not specified. In conclusion, while the study may provide valuable insights, additional methodological clarification could strengthen validity and generalizability. Marc Benninga is a consultant for Shire, Norgine, Coloplast, Danone, Takeda, Allergan, FrieslandCampina, United Pharmaceuticals, and HiPP. The remaining authors declare no conflicts of interest.